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5-FU remains as the mainstay treatment for metastatic colorectal
carcinoma. A combination of 5-FU with leucovorin has received
widespread acceptance in the treatment regimens for this disease,
with a superior response rate than that of 5-FU alone (Advanced
Colorectal Cancer Meta-Analysis Project, 1992). However, even
in this regimen chemotherapy has only palliative impact for
metastatic colorectal carcinoma. Issues regarding cost-effective-
ness have been recently addressed in the field of medical oncology
and will be unavoidable in the near future (DeMario et al, 1998).
Under these circumstances, oral chemotherapy has become a
promising alternative in converting inpatients to outpatients and in
reducing times to visit a hospital. Although the economical benefit
depends on the market prices of oral agents, these agents can
provide a chance to reduce the medical costs. During the period
from the 1970s to the 1980s an oral fluorinated pyrimidine, a
combination of uracil and tegafur (UFT), was originally developed
in Japan and evaluated in Japanese clinical trials (Takiuchi et al,
1998). Uracil is observed to inhibit the activity of hepatic DPD, a
key enzyme in 5-FU catabolism, thus leading to increased 5-FU
levels when tegafur is administered together with uracil (Ikenaka
et al, 1979). There followed widespread use of the agent by Asian
physicians, especially for gastrointestinal malignancies (Takiuchi
et al, 1998). However, because methodology and quality assurance
of the clinical trial were immature at that time, the true impact of
the agent was not assessed and is still uncertain. UFT was re-eval-
uated outside Japan as a single agent as well as in combination
with leucovorin, with promising results (Malik et al, 1990; Pazdur
et al, 1994).
S-1 is a new oral fluorinated pyrimidine developed by Taiho
Pharmaceutical Co Ltd (Tokyo, Japan). The agent contains
tegafur, CDHP and potassium oxonate in a molar ratio of 1:0.4:1,
based on a biochemical modulation of 5-FU (Shirasaka et al,
1996). CDHP exhibits a 180-fold higher activity in inhibiting DPD
than that of uracil in vitro (Tatsumi et al, 1987). Potassium oxonate
inhibits phosphorylation of 5-FU by orotate pyrimidine phospho-
ribosyl transferase in the digestive tract (Houghton et al, 1979).
The levels of 5-fluorouridine 5¢-monophosphate and 5-FU incor-
porated into RNA are reduced to approximately 30% only in the
small intestine, while the decrease is limited to 0–20% in bone
marrow and tumour tissue (Shirasaka et al, 1993). Another experi-
ment in rats bearing subcutaneous Yoshida Sarcoma cells showed
that S-1 tended to prolong the concentration of 5-FU in plasma and
tumour tissue more than an equitoxic dose of UFT, with less
gastrointestinal toxicity (Takechi et al, 1997).
Based on the promising preclinical results, a phase I study of the
agent was conducted in Japan. The study concluded that the
maximum allowable dose of the agent was 75 mg body–1 twice-
daily for 28 consecutive days followed by a 14-day rest period,
with dose-limiting toxicity of leucopenia (Taguchi et al, 1997).
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Summary This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains
tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted
at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled
into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a
standard dose of 80 mg m–2 day–1 for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted
toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25–48%. Five of the 10
patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse
reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less
than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results
suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical
modulation with easily manageable toxicity. © 2000 Cancer Research Campaign
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quent early and late phase II study, which resulted in response rates
of approximately 50% in both studies, with minimal toxicity
(Sugimachi et al, 1999; Sakata et al, 1998). For colorectal carci-
noma, the response was only modest with a rate of 17% in early
phase II study. However, the response rate was 25% in patients
without prior chemotherapy, warranting further research in rela-
tion to this disease. Since the rate of discontinuation due to adverse
reactions was markedly reduced for patients given 90 mg m–2 day–1
or less, 80 mg m–2 day–1 was recommended as the standard dose.
The results of the following late phase II study are described in
this paper.
PATIENTS AND METHODS
Patient eligibility
Patients eligible for this study were required to show histologically
proven colorectal carcinoma with measurable or evaluable lesions.
No prior chemotherapy or radiotherapy except for adjuvant
chemotherapy completed at least 6 months before selection was
allowed. Patients were required to have 2 or better performance
status in Eastern Cooperative Oncology Group scale with a life-
expectancy of 3 months or longer and to be younger than 75 years.
Eligibility also required adequate organ functions: haemoglobin
³ 9.0 g dl–1; WBC ³ 4000–12 000 ml–1; platelets ³ 100 000 ml–1;
AST and ALT ≤ 100 IU l–1; serum alkaline phosphate within twice
the normal upper limit; serum bilirubin ≤ 1.5 mg dl–1; creatinine
within normal upper limit; and written informed consent from the
patients. Only patients that were fit enough to receive chemotherapy,
with no other cancers, were eligible for this study. This study was
approved by each institutional review board and was conducted in
accordance with good clinical practice guideline in Japan.
Treatment schedule
The patients were assigned on the basis of body surface area to
receive one of the following doses twice daily, after breakfast and
dinner: body surface area < 1.25 m2, 40 mg; < 1.50 m2, 50 mg;
³ 1.50 m2, 60 mg. S-1 was administered at the respective dose for
28 days, followed by a 2-week rest period. This schedule was
repeated every 6 weeks until the occurrence of disease progres-
sion, unacceptable toxicities, or patient’s refusal. The dose was
reduced by 20 mg day–1 if grade 3 or higher haematological or
grade 2 or higher non-haematological toxicity was seen in the
previous course. Patients who required more than 4 weeks of rest
to recover from any toxicity other than alopecia or skin toxicity
were retired from the treatment. No prophylactic use of anti-
emetic agents was allowed. Compliance was assessed by patient
interviews with each investigator, using a schedule calendar with
regular monitoring.
Evaluation of response and toxicity
Antitumour activity was evaluated in accordance with the general
rule edited by the Japanese Research Society for Colorectal
Carcinoma based on WHO criteria (Japanese Research Society for
Cancer of Colon and Rectum, 1994). Briefly, a complete response
(CR) was defined as the complete disappearance of all measurable
and assessable diseases for a minimum of 4 weeks. A partial
response (PR) was defined as a 50% or more reduction in the sum
of the products of the longest diameter of measurable disease for
a minimum of 4 weeks. Stable disease (SD) was defined as the
failure to observe a partial or complete response and progressive
disease for at least 4 weeks. Progressive disease (PD) was defined
as a 25% or more increase in the sum of the products of the longest
diameter of measurable disease or the appearance of new lesions.
Objective responses were confirmed by an external review
committee consisting of five oncologists.
Toxicity was evaluated according to the toxicity criteria of the
Japan Society for Cancer Therapy, based on modifications of the
WHO criteria (Japan Society for Cancer Therapy, 1993).
Statistics
The sample size for the study was calculated from an expected
response rate of 20% with an a and b error of 0.05 and 0.2, respec-
tively. Therefore, 60 patients were required in this study. Survival
was calculated from the date of initiation using the Kaplan–Meier
method.
RESULTS
During the period August 1995–March 1997 a total of 63 patients
were enrolled. One patient did not receive the agent because of
rapid progression immediately after registration. This patient was
judged as ineligible and excluded from the analysis. The other 62
patients were considered to be eligible and their characteristics are
listed in Table 1. There were 43 patients with colon and 19 with
rectal carcinoma as the primary site. Forty-eight patients had a
prior history of surgical resection. Ten patients had an additional
history of adjuvant chemotherapy. All 10 adjuvant chemotherapy
patients were treated with a regimen including 5-FU or oral
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Table 1 Patient characteristics
No. of patients
Total eligible patients 62
Primary site
Colon 43
Rectum 19
Sex
Male 37
Female 25
Age (years)
Median 62
Range 27–74
ECOG performance status scale
03 6
11 9
27
Initial dosage (mg day–1)
80 4
100 25
120 33
Prior surgical resection (primary)
Yes 48
No 14
Adjuvant chemotherapy
Yes 10
No 52
ECOG = Eastern Cooperative Oncology Groupfluorinated pyrimidines, predominantly UFT. Only one patient had
received pelvic radiotherapy.
A total of 271 courses were administered to the 62 patients with
a median of four courses. Fifty-three (85%) of the 62 patients were
treated as outpatients. The other nine patients received the agent as
inpatients because of easier management or patient’s preference,
which is usual in Japanese clinical trials associated with low hospi-
talization cost. No patients required dose reduction due to adverse
reactions. Compliance was extremely good with an actual admin-
istration rate of 97%.
Twenty-two (35%) of the 62 patients achieved PR with a 95%
confidence interval of 25–48%. Responses for each of the target
sites were 39% in lung, 28% in liver, and 50% in abdominal node
metastases (Table 2). Five of the 10 patients with a history of adju-
vant chemotherapy achieved PR. There were no significant differ-
ences in response rates by actually administered doses per body
surface area. Patients administered < 70, < 75, and ³ 75 mg m–2
day–1 of the agents, achieved response rates of 44, 30, and 35%, in
16, 23, and 23 patients, respectively. The median time to achieve a
50% reduction of the tumour and median response duration were
37 (23–85) days and 171 (78–389) days, respectively. The median
survival time of the 62 patients was 12 months with a 2-year
survival rate of 21% (Figure 1).
The most serious adverse reactions during the treatment are
listed in Table 3. Major adverse reactions included myelosuppres-
sive and gastrointestinal toxicities, though they were generally
mild and no treatment-related deaths occurred. Five (8%) patients
developed grade 4 thrombocytopenia, three in the first, of whom
one was associated with grade 4 neutropenia, one in the second,
and one in the fourth course of the treatment. Grade 4 leukopenia
was also seen in two (5%) patients. There was one early death on
day 21 caused by hyperosmolar diabetic coma, where the patient
had diabetes mellitus before commencement of the treatment. No
other grade 4 toxicity occurred during the study. Only one patient
developed either grade 3 nausea or grade 3 vomiting and diarrhea.
Skin toxicities were rarely seen, with occurence in less than 10%
of the patients, except for skin pigmentation which was seen in
18%. Incidence of grade 3 or 4 toxicity tended to be higher in
patients administered 70 mg m–2 day–1 or more than those
receiving less than 70 mg m–2 day–1, 39% vs 13% (P = 0.098)
respectively. None of the 53 patients treated as outpatients required
hospitalization due to adverse reactions.
DISCUSSION
Two major advantages have been reported in oral chemotherapy,
one being pharmacoeconomic and the other being patient prefer-
ence (DeMario et al, 1998). Cost will become a central issue
particularly in palliative settings such as chemotherapy for
metastatic colorectal carcinoma. In response to issues relating to
the administrative cost of this disease, future trends should be
directed to outpatient chemotherapy. The issue of patient prefer-
ence has been reported by Liu et al (1997). The study revealed that
more than 90% of the patients with advanced solid malignancies
preferred oral agents if they provided comparable efficacy to infu-
sional agents. In the present study, most of the patients were
treated as outpatients without requiring hospitalization for adverse
reactions. The agent S-1 also exhibited similar efficacy to, for
instance, a combination of infusional 5FU plus leucovorin, with
less toxicities. These results appeared to fulfill the major prefer-
ences for oral agents.
Bioavailability and interpatient biovariability are usually major
problems that are required to be elucidated in oral agents. From the
in vivo study using rats, the bioavailability of S-1 was found to be
102% with respect to tegafur, though it was 58% and 25% with
respect to CDHP and potassium oxonate respectively. In the
previous phase I study, sufficient plasma concentration of 5-FU,
more than 100 ng ml–1, was achieved with the patients treated at
the dose and schedule regimen employed in the present study
(Taguchi et al, 1997). Interpatient AUC variability appeared to be
small with a lower frequency of critical toxicity, which shows a
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Figure 1 Overall survival of the 62 eligible patients.
Table 2 Response results
Response
Patients (n) CR PR NC PD NE rate (%)
Overall 62 0 22 28 8 4 35.5*
Colon 43 0 15 19 7 2 34.9
Rectum 19 0 7 9 1 2 36.8
Metastatic site
Liver 40 1 10 20 6 3 27.5
Lung 28 0 11 15 1 1 39.3
Others 14 1 4 4 2 3 35.7
CR = Complete Response; PR = Partial Response; NC = No Change;
PD = Progressive Disease; NE = Not Evaluated. *95% confidence interval,
24.7–47.9%
Table 3 Toxicity
Grade Incidence of
Toxicity (No. of patients) ³ Grade 3
1 2 3 4 (%)
Haematological
Leukopenia 17 10 1 2 4.8
Neutropenia 4 11 7 1 12.9
Anaemia 5 11 4 0 6.5
Thrombocytopenia 5 2 0 5 8.1
Non-haematological
Stomatitis 8 2 0 0 –
Diarrhoea 2 6 1 0 1.6
Anorexia 7 11 3 0 4.8
Nausea/vomiting 7 4 1 0 1.6
Skin rash 2 4 0 0 –
Pigmentation 11 0 0 0 –
Malaise 9 2 1 0 1.6general correlation with the pharmacodynamics. These two phar-
macokinetic parameters provided enough information to elucidate
the major problems affecting the efficacy of this oral agent. The
present study also revealed clinical activity for colorectal carci-
noma with a response rate of 35%, which seemed to be compa-
rable to those in other combination regimens such as 5-FU plus
leucovorin (The Advanced Colorectal Cancer Meta-Analysis
Project, 1992; Poon et al, 1989; Petrelli et al, 1989; Leichman,
1995). Although myelosuppression of this agent tended to be
higher than those of UFT with or without leucovorin, the incidence
of grade 3 or 4 toxicities was only less than 13%. The survival rate
of the present study, with a median survival time of 12 months,
also demonstrated similar results to those in the standard 5-FU and
leucovorin regimen. Based on these pharmacokinetic and clinical
outcomes, S-1 may provide clinical benefits comparable with
intravenous combination regimens.
DPD is known to be the initial and rate-limiting enzyme
affecting 5-FU catabolism, converting approximately 90% of
administered 5-FU to a-fluoro-b-alanine (Heggie et al, 1987). The
importance of this enzyme was first recognized from the critical
toxicity in deficient patients (Tuchman et al, 1985; Diasio et al,
1988) followed by circadian rhythm of its activity and chronomod-
ulated therapy (Harris et al, 1990; Levi et al, 1992). Recently, DPD
has also been pointed out as a determining factor regarding its
sensitivity to 5-FU. Etienne et al 1995) reported that DPD activity
in pretreatment tumour tissues correlated to a clinical response
with thymidylate synthase activity in patients with head and neck
cancer treated with 5-FU-based chemotherapy. This evidence was
compounded by a rationale involving a biochemical modulation of
5-FU using a DPD inhibitor, eniluracil (Baccanari et al, 1993;
Schilsky et al, 1997). Schilsky et al 1997) reported a 33% response
rate using an oral 5-day schedule of 5-FU at 20 mg m–2, leucovorin
at 50 mg day–1, and eniluracil at 20 mg day–1. However, the inhibi-
tion of DPD by this agent is irreversible, with possible toxicity. As
a result, the above regimen was associated with significant
neutropenia, which required hospitalization in 10 of the 24 patients
registered. In contrast, CDHP contained in S-1 is a reversible DPD
inhibitor and our results indicated mostly mild toxicity without
hospitalization or cumulative toxicity. Five of the 10 patients with
a history of adjuvant chemotherapy containing 5-FU achieved
objective responses, suggesting a biochemical modulation effect
by CDHP.
Our data, including the previous study, suggest that S-1
achieves similar responses to a standard regimen of 5-FU plus
leucovorin and shows the potential of being an alternative to that
combination. The agent also exhibited easily manageable toxicity
and was readily accepted by our patients. Further investigations of
the agent including a randomized trial are warranted.
ACKNOWLEDGEMENTS
We are grateful to Drs K Ota, S Tsukagoshi, I Nakao, H and Furue,
for kind advice, Drs W Koizumi, J Ota, N Hirabayashi and 
Y Maehara for extramural review and many other participants of
the S-1 Cooperative Colorectal Carcinoma Study Group during 
the study. We also thank T Tahara, M Dantsuji, K Iizuka, K
Hoashi,H Anbe and K Okabe for assistance in data collection 
and analysis. This study was supported by Taiho Pharmaceutical
Co Ltd,Tokyo.
REFERENCES
Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of
fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin
Oncol 10: 896–903
Baccanari DP, Davis ST, Knick VC and Spector T (1993) 776C85: Effects on the
pharmacokinetics and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci
USA 90: 11064–11068
DeMario MD and Ratain MJ (1998) Oral chemotherapy: rationale and future
directions. J Clin Oncol 16: 2557–2567
Diasio RB, Beavers TL and Carpenter JT (1988) Familial deficiency of
dihydropyrimidine dehydrogenase. J Clin Invest 81: 47–51
Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N,
Schneider M, Thyss A, Demard F and Milano G (1995) Response to
fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine
dehydrogenase activity. J Clin Oncol 13: 1663–1670
Harris BE, Song R, Soong SJ and Diasio RB (1990) Relationship between
dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels
with evidence for circadian variation of enzyme activity and plasma drug levels
in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Cancer Res 50: 197–201
Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB (1987) Clinical
pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and
bile. Cancer Res 47: 2203–2206
Houghton JA, Houghton PJ and Wooten RS (1979) Mechanism of induction of
gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and
5-fluoro-2’-deoxyuridine. Cancer Res 39: 2406–2413
Ikenaka K, Shirasaka T and Kitano S (1979) Effect of uracil on metabolism o
5-fluorouracil in vitro. Jpn J Cancer Res 70: 353–359
Japanese Research Society for Cancer of Colon and Rectum (1994) General rules
for clinical and pathological studies on cancer of the colon, rectum and anus.
5th edn. Kanehara Syuppan: Tokyo
Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical
effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101–130
Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP,
Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H and
Reinberg A (1992) A chronopharmacologic phase II clinical trial with
5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel
programmable pump. Cancer 69: 893–900
Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH,
Meyers FJ, Holcombe RF, Weiss GR, Mangalik A and Macdonald JS (1995)
Phase II study of fluorouracil and its modulation in advanced colorectal cancer:
A Southwest Oncology Group Study. J Clin Oncol 13: 1303–1311
Liu G, Franssen E, Fitch MI and Warner E (1997) Patient preference for oral versus
intravenous palliative chemotherapy. J Clin Oncol 15: 110–115
Malik ST, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PF and Slevin ML
(1990) Phase II trial of UFT in advanced colorectal and gastric cancer. Br J
Cancer 62: 1023–1025
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr,
Markowitz AB, Abbruzzese JL, Bready B and Levin B (1994) Phase II trial of
uracil and tegafur plus oral leucovorin: An effective oral regimen in the
treatment of metastatic colorectal carcinoma. J Clin Oncol 12:
2296–2300
Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW,
Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES,
Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS,
Benedetto P, Woolley PV, Nauta R, Weaver DW and Leichman LP for the
gastrointestinal tumor study group (1989) The modulation of fuorouracil with
leucovorin in metastatic colorectal carcinoma: A prospective randomized phase
III trial. J Clin Oncol 7: 1419–1426
Poon MA, O’Connel MJ, Moertel CG, Wieand HS, Cullina SA, Everson LK, Krook
JE, Mailliard JA, Laurie JA, Tschetter LK and Wiesenfeld M (1989)
Biochemical modulation of fluorouracil: Evidence of significant improvement
of survival and quality of life in patients with advanced colorectal carcinoma.
J Clin Oncol 7: 1407–1418
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T (1998)
Late phase II study of novel oral fluoropyrimidine anticancer drugs S-1
(1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer
patients. Eur J Cancer 34: 1715–1720
Schilsky R, Bukowski R, Burris H, Crawford J, Hochster H, O’Rourke M, Steinfeldt
H, Doucette M, Levin J and Hohneker J (1997) A phase II study of a five day
regimen of 5-fluorouracil (5-FU) plus GW776 (776C85) with or without
144 A Ohtsu et al
British Journal of Cancer (2000) 83(2), 141–145 © 2000 Cancer Research Campaignleucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncl
16: 271a (abst 961)
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe,
H Oyama K, Takeda S, Unemi N and Fukushima M (1996) Antitumor activity
of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate
(S-1) against human colon carcinoma orthotopically implanted into nude rats.
Cancer Res 56: 2602–2606
Shirasaka T, Shimamoto Y and Fukushima M (1993) Inhibition by oxonic acid of
gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity
in rats. Cancer Res 53: 4004–4009
Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T
and The S-1 Gastrointestinal Cancer Study Group (1999) An early phase II
study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and
recurrent gastrointestinal cancers. Oncology 57: 202–210
Takiuchi H and Ajani JA (1998) Uracil-tegafur in gastric carcinoma: a
comprehensive review. J Clin Oncol 16: 2877–2885
Tatsumi K, Fukushima M, Shirasaka T and Fujii S (1987) Inhibitory effects of
pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil
degradation in rat liver extracts. Jpn J Cancer Res 78: 748–755
Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N and Shirasaka
T (1997) Antitumor activity and low intestinal toxicity of S-1, a new
formulation of oral tegafur, in experimental tumor models in rats. Cancer
Chemother Pharmacol 39: 205–211
Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H,
Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T,
Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S
and Nakao I (1997) Phase I study of S-1. Jpn J Cancer Chemother 24(15):
2253–2264
Tuchman M, Stoeckeler JS, Kiang DT, O’Dea RF, Ramnaraine ML and Mirkin BL
(1985) Familial pyrimidinemia and pyrimidinuria associated with severe
fluorouracil toxicity. N Engl J Med 313: 245–249
S-1 for colorectal carcinoma 145
British Journal of Cancer (2000) 83(2), 141–145 © 2000 Cancer Research Campaign146 A Ohtsu et al
British Journal of Cancer (2000) 83(2), 141–145 © 2000 Cancer Research Campaign